The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and ...

A Food and Drug Administration expert panel has reignited a debate over whether hormone therapy should be used to treat ...

Astellas’ menopause treatment has been accepted for FDA review, five months after the therapy hit a speed bump in a phase 3 trial conducted in Asia.

The panelists said that vaginal creams and other localized therapies for menopause are safe and vastly underused by women who ...

Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...

A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...

A decades-old label has scared women (and their doctors) away from safe and effective menopause treatment. That could finally change today.

The debate over whether to use hormone therapy to treat menopausal women continues, as a Food and Drug Administration (FDA) expert panel weighs in. The panel, consisting […] ...

Experts worry the warning on vaginal estrogen menopause treatments is doing more harm than good and is not supported by science.

The FDA approved TherapeuticsMD’s hormone therapy Imvexxy for a vaginal condition linked to low estrogen levels during menopause, the company announced May 30. 1. Imvexxy is intended to treat ...

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

Bioidentical or plant-derived hormones have uncertain efficacy or safety in treating menopausal symptoms. What is the evidence supporting the use of compounded and FDA-approved bioidentical products?